Cellectis (CLLS) Curent Deferred Tax Liability (2024)

Cellectis' (CLLS) quarterly Curent Deferred Tax Liability came in at $122000.0 in Q2 2024, down 10.95% quarter-over-quarter from $137000.0 in Q1 2024.

Cellectis (CLLS) Curent Deferred Tax Liability (2024) Analysis & Trends

Cellectis' Curent Deferred Tax Liability history runs 1 years deep, the most recent figure standing at $122000.0 for Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Curent Deferred Tax (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Cellectis 281.48 Mn 95.81 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2024 122,000.00
Jun 30, 2024 122,000.00
Mar 31, 2024 137,000.00
Mar 31, 2024 137,000.00